To evaluate the plasma trough concentrations (Ctrough) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis. Virological efficacy and safety of both ART and anti-HCV therapy were assessed.

Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis

MARINARO, Letizia;ARIAUDO, ALESSANDRA;D'AVOLIO, ANTONIO;BONORA, Stefano;
2017

Abstract

To evaluate the plasma trough concentrations (Ctrough) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis. Virological efficacy and safety of both ART and anti-HCV therapy were assessed.
72
3
812
815
Merli, Marco; Galli, Laura; Marinaro, Letizia; Ariaudo, Alessandra; Messina, Emanuela; Uberti-Foppa, Caterina; Castagna, Antonella; D'Avolio, Antonio; Lazzarin, Adriano; Bonora, Stefano; Hasson, Hamid
File in questo prodotto:
File Dimensione Formato  
dkw492.pdf

non disponibili

Tipo di file: PDF EDITORIALE
Dimensione 153.15 kB
Formato Adobe PDF
153.15 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1635827
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact